A protein found on T cells (a type of immune cell) that helps keep the body's immune responses in check. When?PD-1?is bound to another protein called?PD-L1, it helps keep T cells from killing other cells, including cancer cells. Some anticancer drugs, called immune checkpoint inhibitors, are used to block?PD-1.
This report aims to provide a comprehensive presentation of the global market for PD-1&PD-L1 Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1&PD-L1 Immunotherapy. This report contains market size and forecasts of PD-1&PD-L1 Immunotherapy in global, including the following market information:
Global PD-1&PD-L1 Immunotherapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global PD-1&PD-L1 Immunotherapy Market Sales, 2018-2023, 2024-2030, (Units)
Global top five PD-1&PD-L1 Immunotherapy companies in 2022 (%)
The global PD-1&PD-L1 Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
PD-1 Inhibitors Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of PD-1&PD-L1 Immunotherapy include AstraZeneca Plc, BeiGene, Ltd., Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Innovent Biologics, Inc. and Jiangsu HengRui Medicine Co., Ltd., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the PD-1&PD-L1 Immunotherapy manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PD-1&PD-L1 Immunotherapy Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global PD-1&PD-L1 Immunotherapy Market Segment Percentages, by Type, 2022 (%)
PD-1 Inhibitors
PD-L1 Inhibitors
Global PD-1&PD-L1 Immunotherapy Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global PD-1&PD-L1 Immunotherapy Market Segment Percentages, by Application, 2022 (%)
Non-Small Cell Lung Cancer
Esophageal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Others
Global PD-1&PD-L1 Immunotherapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global PD-1&PD-L1 Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies PD-1&PD-L1 Immunotherapy revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies PD-1&PD-L1 Immunotherapy revenues share in global market, 2022 (%)
Key companies PD-1&PD-L1 Immunotherapy sales in global market, 2018-2023 (Estimated), (Units)
Key companies PD-1&PD-L1 Immunotherapy sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca Plc
BeiGene, Ltd.
Bristol-Myers Squibb Company
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Eli Lilly & Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Innovent Biologics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.
Outline of Major Chapters:
Chapter 1: Introduces the definition of PD-1&PD-L1 Immunotherapy, market overview.
Chapter 2: Global PD-1&PD-L1 Immunotherapy market size in revenue and volume.
Chapter 3: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PD-1&PD-L1 Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global PD-1&PD-L1 Immunotherapy capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 PD-1&PD-L1 Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global PD-1&PD-L1 Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global PD-1&PD-L1 Immunotherapy Overall Market Size
2.1 Global PD-1&PD-L1 Immunotherapy Market Size: 2022 VS 2030
2.2 Global PD-1&PD-L1 Immunotherapy Revenue, Prospects & Forecasts: 2018-2030
2.3 Global PD-1&PD-L1 Immunotherapy Sales: 2018-2030
3 Company Landscape
3.1 Top PD-1&PD-L1 Immunotherapy Players in Global Market
3.2 Top Global PD-1&PD-L1 Immunotherapy Companies Ranked by Revenue
3.3 Global PD-1&PD-L1 Immunotherapy Revenue by Companies
3.4 Global PD-1&PD-L1 Immunotherapy Sales by Companies
3.5 Global PD-1&PD-L1 Immunotherapy Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 PD-1&PD-L1 Immunotherapy Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers PD-1&PD-L1 Immunotherapy Product Type
3.8 Tier 1, Tier 2 and Tier 3 PD-1&PD-L1 Immunotherapy Players in Global Market
3.8.1 List of Global Tier 1 PD-1&PD-L1 Immunotherapy Companies
3.8.2 List of Global Tier 2 and Tier 3 PD-1&PD-L1 Immunotherapy Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global PD-1&PD-L1 Immunotherapy Market Size Markets, 2022 & 2030
4.1.2 PD-1 Inhibitors
4.1.3 PD-L1 Inhibitors
4.2 By Type - Global PD-1&PD-L1 Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global PD-1&PD-L1 Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global PD-1&PD-L1 Immunotherapy Revenue, 2024-2030
4.2.3 By Type - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
4.3 By Type - Global PD-1&PD-L1 Immunotherapy Sales & Forecasts
4.3.1 By Type - Global PD-1&PD-L1 Immunotherapy Sales, 2018-2023
4.3.2 By Type - Global PD-1&PD-L1 Immunotherapy Sales, 2024-2030
4.3.3 By Type - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
4.4 By Type - Global PD-1&PD-L1 Immunotherapy Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global PD-1&PD-L1 Immunotherapy Market Size, 2022 & 2030
5.1.2 Non-Small Cell Lung Cancer
5.1.3 Esophageal Cancer
5.1.4 Urothelial Carcinoma
5.1.5 Hepatocellular Carcinoma
5.1.6 Small Cell Lung Cancer
5.1.7 Others
5.2 By Application - Global PD-1&PD-L1 Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global PD-1&PD-L1 Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global PD-1&PD-L1 Immunotherapy Revenue, 2024-2030
5.2.3 By Application - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
5.3 By Application - Global PD-1&PD-L1 Immunotherapy Sales & Forecasts
5.3.1 By Application - Global PD-1&PD-L1 Immunotherapy Sales, 2018-2023
5.3.2 By Application - Global PD-1&PD-L1 Immunotherapy Sales, 2024-2030
5.3.3 By Application - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
5.4 By Application - Global PD-1&PD-L1 Immunotherapy Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global PD-1&PD-L1 Immunotherapy Market Size, 2022 & 2030
6.2 By Region - Global PD-1&PD-L1 Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global PD-1&PD-L1 Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global PD-1&PD-L1 Immunotherapy Revenue, 2024-2030
6.2.3 By Region - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
6.3 By Region - Global PD-1&PD-L1 Immunotherapy Sales & Forecasts
6.3.1 By Region - Global PD-1&PD-L1 Immunotherapy Sales, 2018-2023
6.3.2 By Region - Global PD-1&PD-L1 Immunotherapy Sales, 2024-2030
6.3.3 By Region - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.4.2 By Country - North America PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.4.3 US PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.4.4 Canada PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.4.5 Mexico PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.5.2 By Country - Europe PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.5.3 Germany PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.4 France PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.5 U.K. PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.6 Italy PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.7 Russia PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.8 Nordic Countries PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.9 Benelux PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.6.2 By Region - Asia PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.6.3 China PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.4 Japan PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.5 South Korea PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.6 Southeast Asia PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.7 India PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.7.2 By Country - South America PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.7.3 Brazil PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.7.4 Argentina PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.8.3 Turkey PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8.4 Israel PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8.5 Saudi Arabia PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8.6 UAE PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 AstraZeneca Plc
7.1.1 AstraZeneca Plc Company Summary
7.1.2 AstraZeneca Plc Business Overview
7.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Major Product Offerings
7.1.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.1.5 AstraZeneca Plc Key News & Latest Developments
7.2 BeiGene, Ltd.
7.2.1 BeiGene, Ltd. Company Summary
7.2.2 BeiGene, Ltd. Business Overview
7.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.2.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.2.5 BeiGene, Ltd. Key News & Latest Developments
7.3 Bristol-Myers Squibb Company
7.3.1 Bristol-Myers Squibb Company Company Summary
7.3.2 Bristol-Myers Squibb Company Business Overview
7.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Major Product Offerings
7.3.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.3.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
7.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Summary
7.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
7.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Key News & Latest Developments
7.5 Eli Lilly & Company
7.5.1 Eli Lilly & Company Company Summary
7.5.2 Eli Lilly & Company Business Overview
7.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Major Product Offerings
7.5.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.5.5 Eli Lilly & Company Key News & Latest Developments
7.6 F. Hoffmann-La Roche Ltd
7.6.1 F. Hoffmann-La Roche Ltd Company Summary
7.6.2 F. Hoffmann-La Roche Ltd Business Overview
7.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Major Product Offerings
7.6.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.6.5 F. Hoffmann-La Roche Ltd Key News & Latest Developments
7.7 GlaxoSmithKline plc
7.7.1 GlaxoSmithKline plc Company Summary
7.7.2 GlaxoSmithKline plc Business Overview
7.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Major Product Offerings
7.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.7.5 GlaxoSmithKline plc Key News & Latest Developments
7.8 Innovent Biologics, Inc.
7.8.1 Innovent Biologics, Inc. Company Summary
7.8.2 Innovent Biologics, Inc. Business Overview
7.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.8.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.8.5 Innovent Biologics, Inc. Key News & Latest Developments
7.9 Jiangsu HengRui Medicine Co., Ltd.
7.9.1 Jiangsu HengRui Medicine Co., Ltd. Company Summary
7.9.2 Jiangsu HengRui Medicine Co., Ltd. Business Overview
7.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.9.5 Jiangsu HengRui Medicine Co., Ltd. Key News & Latest Developments
7.10 Merck & Co., Inc.
7.10.1 Merck & Co., Inc. Company Summary
7.10.2 Merck & Co., Inc. Business Overview
7.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.10.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.10.5 Merck & Co., Inc. Key News & Latest Developments
7.11 Novartis AG
7.11.1 Novartis AG Company Summary
7.11.2 Novartis AG PD-1&PD-L1 Immunotherapy Business Overview
7.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Major Product Offerings
7.11.4 Novartis AG PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.11.5 Novartis AG Key News & Latest Developments
7.12 Pfizer Inc.
7.12.1 Pfizer Inc. Company Summary
7.12.2 Pfizer Inc. PD-1&PD-L1 Immunotherapy Business Overview
7.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.12.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.12.5 Pfizer Inc. Key News & Latest Developments
7.13 Regeneron Pharmaceuticals Inc.
7.13.1 Regeneron Pharmaceuticals Inc. Company Summary
7.13.2 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Business Overview
7.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.13.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.13.5 Regeneron Pharmaceuticals Inc. Key News & Latest Developments
7.14 Sanofi S.A.
7.14.1 Sanofi S.A. Company Summary
7.14.2 Sanofi S.A. Business Overview
7.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.14.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.14.5 Sanofi S.A. Key News & Latest Developments
8 Global PD-1&PD-L1 Immunotherapy Production Capacity, Analysis
8.1 Global PD-1&PD-L1 Immunotherapy Production Capacity, 2018-2030
8.2 PD-1&PD-L1 Immunotherapy Production Capacity of Key Manufacturers in Global Market
8.3 Global PD-1&PD-L1 Immunotherapy Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 PD-1&PD-L1 Immunotherapy Supply Chain Analysis
10.1 PD-1&PD-L1 Immunotherapy Industry Value Chain
10.2 PD-1&PD-L1 Immunotherapy Upstream Market
10.3 PD-1&PD-L1 Immunotherapy Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 PD-1&PD-L1 Immunotherapy Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of PD-1&PD-L1 Immunotherapy in Global Market
Table 2. Top PD-1&PD-L1 Immunotherapy Players in Global Market, Ranking by Revenue (2022)
Table 3. Global PD-1&PD-L1 Immunotherapy Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global PD-1&PD-L1 Immunotherapy Revenue Share by Companies, 2018-2023
Table 5. Global PD-1&PD-L1 Immunotherapy Sales by Companies, (Units), 2018-2023
Table 6. Global PD-1&PD-L1 Immunotherapy Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers PD-1&PD-L1 Immunotherapy Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers PD-1&PD-L1 Immunotherapy Product Type
Table 9. List of Global Tier 1 PD-1&PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 PD-1&PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global PD-1&PD-L1 Immunotherapy Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global PD-1&PD-L1 Immunotherapy Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global PD-1&PD-L1 Immunotherapy Sales (Units), 2018-2023
Table 15. By Type - Global PD-1&PD-L1 Immunotherapy Sales (Units), 2024-2030
Table 16. By Application ? Global PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global PD-1&PD-L1 Immunotherapy Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global PD-1&PD-L1 Immunotherapy Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global PD-1&PD-L1 Immunotherapy Sales (Units), 2018-2023
Table 20. By Application - Global PD-1&PD-L1 Immunotherapy Sales (Units), 2024-2030
Table 21. By Region ? Global PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global PD-1&PD-L1 Immunotherapy Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global PD-1&PD-L1 Immunotherapy Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global PD-1&PD-L1 Immunotherapy Sales (Units), 2018-2023
Table 25. By Region - Global PD-1&PD-L1 Immunotherapy Sales (Units), 2024-2030
Table 26. By Country - North America PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America PD-1&PD-L1 Immunotherapy Sales, (Units), 2018-2023
Table 29. By Country - North America PD-1&PD-L1 Immunotherapy Sales, (Units), 2024-2030
Table 30. By Country - Europe PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe PD-1&PD-L1 Immunotherapy Sales, (Units), 2018-2023
Table 33. By Country - Europe PD-1&PD-L1 Immunotherapy Sales, (Units), 2024-2030
Table 34. By Region - Asia PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia PD-1&PD-L1 Immunotherapy Sales, (Units), 2018-2023
Table 37. By Region - Asia PD-1&PD-L1 Immunotherapy Sales, (Units), 2024-2030
Table 38. By Country - South America PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America PD-1&PD-L1 Immunotherapy Sales, (Units), 2018-2023
Table 41. By Country - South America PD-1&PD-L1 Immunotherapy Sales, (Units), 2024-2030
Table 42. By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Sales, (Units), 2018-2023
Table 45. By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Sales, (Units), 2024-2030
Table 46. AstraZeneca Plc Company Summary
Table 47. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Offerings
Table 48. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. AstraZeneca Plc Key News & Latest Developments
Table 50. BeiGene, Ltd. Company Summary
Table 51. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Offerings
Table 52. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. BeiGene, Ltd. Key News & Latest Developments
Table 54. Bristol-Myers Squibb Company Company Summary
Table 55. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Offerings
Table 56. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Bristol-Myers Squibb Company Key News & Latest Developments
Table 58. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Summary
Table 59. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Offerings
Table 60. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Key News & Latest Developments
Table 62. Eli Lilly & Company Company Summary
Table 63. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Offerings
Table 64. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Eli Lilly & Company Key News & Latest Developments
Table 66. F. Hoffmann-La Roche Ltd Company Summary
Table 67. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Offerings
Table 68. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. F. Hoffmann-La Roche Ltd Key News & Latest Developments
Table 70. GlaxoSmithKline plc Company Summary
Table 71. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Offerings
Table 72. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. GlaxoSmithKline plc Key News & Latest Developments
Table 74. Innovent Biologics, Inc. Company Summary
Table 75. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Offerings
Table 76. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Innovent Biologics, Inc. Key News & Latest Developments
Table 78. Jiangsu HengRui Medicine Co., Ltd. Company Summary
Table 79. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Offerings
Table 80. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Jiangsu HengRui Medicine Co., Ltd. Key News & Latest Developments
Table 82. Merck & Co., Inc. Company Summary
Table 83. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Offerings
Table 84. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Merck & Co., Inc. Key News & Latest Developments
Table 86. Novartis AG Company Summary
Table 87. Novartis AG PD-1&PD-L1 Immunotherapy Product Offerings
Table 88. Novartis AG PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Novartis AG Key News & Latest Developments
Table 90. Pfizer Inc. Company Summary
Table 91. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Offerings
Table 92. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Pfizer Inc. Key News & Latest Developments
Table 94. Regeneron Pharmaceuticals Inc. Company Summary
Table 95. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Offerings
Table 96. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Regeneron Pharmaceuticals Inc. Key News & Latest Developments
Table 98. Sanofi S.A. Company Summary
Table 99. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Offerings
Table 100. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. Sanofi S.A. Key News & Latest Developments
Table 102. PD-1&PD-L1 Immunotherapy Production Capacity (Units) of Key Manufacturers in Global Market, 2021-2023 (Units)
Table 103. Global PD-1&PD-L1 Immunotherapy Capacity Market Share of Key Manufacturers, 2021-2023
Table 104. Global PD-1&PD-L1 Immunotherapy Production by Region, 2018-2023 (Units)
Table 105. Global PD-1&PD-L1 Immunotherapy Production by Region, 2024-2030 (Units)
Table 106. PD-1&PD-L1 Immunotherapy Market Opportunities & Trends in Global Market
Table 107. PD-1&PD-L1 Immunotherapy Market Drivers in Global Market
Table 108. PD-1&PD-L1 Immunotherapy Market Restraints in Global Market
Table 109. PD-1&PD-L1 Immunotherapy Raw Materials
Table 110. PD-1&PD-L1 Immunotherapy Raw Materials Suppliers in Global Market
Table 111. Typical PD-1&PD-L1 Immunotherapy Downstream
Table 112. PD-1&PD-L1 Immunotherapy Downstream Clients in Global Market
Table 113. PD-1&PD-L1 Immunotherapy Distributors and Sales Agents in Global Market
List of Figures
Figure 1. PD-1&PD-L1 Immunotherapy Segment by Type in 2022
Figure 2. PD-1&PD-L1 Immunotherapy Segment by Application in 2022
Figure 3. Global PD-1&PD-L1 Immunotherapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global PD-1&PD-L1 Immunotherapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global PD-1&PD-L1 Immunotherapy Revenue, 2018-2030 (US$, Mn)
Figure 7. PD-1&PD-L1 Immunotherapy Sales in Global Market: 2018-2030 (Units)
Figure 8. The Top 3 and 5 Players Market Share by PD-1&PD-L1 Immunotherapy Revenue in 2022
Figure 9. By Type - Global PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 11. By Type - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 12. By Type - Global PD-1&PD-L1 Immunotherapy Price (US$/Unit), 2018-2030
Figure 13. By Application - Global PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 15. By Application - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 16. By Application - Global PD-1&PD-L1 Immunotherapy Price (US$/Unit), 2018-2030
Figure 17. By Region - Global PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 20. By Region - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 21. By Country - North America PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 22. By Country - North America PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 23. US PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 24. Canada PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 27. By Country - Europe PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 28. Germany PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 29. France PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 31. Italy PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 32. Russia PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 36. By Region - Asia PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 37. China PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 38. Japan PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 41. India PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 43. By Country - South America PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 44. Brazil PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
Figure 48. Turkey PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 49. Israel PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 51. UAE PD-1&PD-L1 Immunotherapy Revenue, (US$, Mn), 2018-2030
Figure 52. Global PD-1&PD-L1 Immunotherapy Production Capacity (Units), 2018-2030
Figure 53. The Percentage of Production PD-1&PD-L1 Immunotherapy by Region, 2022 VS 2030
Figure 54. PD-1&PD-L1 Immunotherapy Industry Value Chain
Figure 55. Marketing Channels
